Clinical Study of " Jin's Three-Needle Therapy in Regulating Spirit Technique " in Treating PD Cognitive Impairment Based on Bibliometrics Analysis

INTERVENTION: Acupuncture plus drug group (treatment group):The Four Divine Needles, Shenting, Yintang, Shenmen, and Sanyinjiao. After the needles are inserted into the above‐mentioned acupoints to obtain qi, the needles should be retained for 30 minutes without applying electricity. During the acupuncture treatment, the patient should take the following drugs simultaneously: doblazide and donepezil, maintaining the original effective therapeutic dose.;Sham acupuncture plus drug group (Control group 1):The acupoint selection was the same as that of the acupuncture plus drug group. A blunt needle was used to apply the needle at a distance of 2 cm beside the true acupoint, non‐through and non‐acupoint. The needle tip touched the skin but did not penetrate (depth 0 mm). Concurrent medication: dopazid and donepezil, maintaining the patients original effective therapeutic dose.;Drug group (Control group 2):The patient took dopazid and donepezil to maintain the original effective therapeutic dose for the patient.; CONDITION: Parkinson's disease cognitive impairment PRIMARY OUTCOME: Montreal Cognitive Assessment;UPDRS‐III scale; SECONDARY OUTCOME: Serological testing: Amyloid Beta 42;Serological testing: Phosphorylated Tau at threonine 181;Serological testing: Glial Fibrillary Acidic Protein; INCLUSION CRITERIA: 1) Meet the diagnostic criteria for PD, and have been treated with dodopazid and donepezil for at least 3 months with stable doses, and the condition is in a stable phase. 2) Male or female, aged 30 to 80. 3) Total score of the Montreal Cognitive Scale (MoCA) is less than 25 points 4) The subjects were informed of the protocol and signed the informed consent form. 5) Patients with stable chronic diseases (such as hypertension, type 2 diabetes, etc.) are allowed to be enrolled, but their related treatment drugs (such as antihypertensive drugs, hypoglycemic drugs) must maintain a stable dose for at least 3 months before enrollment, and their conditions must be well controlled, and the drugs they are taking do not affect the assessment of this study.